Compare VanEck Gold Miners ETF (GDX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Viatris Inc — how do they compare? VanEck Gold Miners ETF trades at $71.97, while Viatris Inc trades at $17.29 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while VanEck Gold Miners ETF pays none, and Viatris Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | VTRS | |
|---|---|---|
52-Week High | $115.84 | $17.39 |
52-Week Low | $51.15 | $8.74 |
Market Cap | — | $19.44B |
Sector | — | Health |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The VanEck Gold Miners ETF (GDX) is trading at $71.97, down 3.89% over the past 24 hours, with a strong bearish technical signal from moving averages. The fund provides exposure to senior gold mining equities, which are currently trading at historically low valuations according to recent analysis, with forward P/E and EV/EBITDA multiples at five-year lows. Recent news highlights ongoing comparisons with lower-fee bullion ETFs and debates about the optimal vehicle for gold exposure.
The outlook presents a dichotomy: attractive valuation metrics and record free cash flow yields suggest potential upside if gold prices rally, while technical weakness and competition from more efficient gold ETFs pose significant risks. A re-rating to historical valuation norms could imply 20% upside, but the fund's performance remains heavily dependent on gold price movements and mining company operational execution.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
